BIOBV — Biohit Oyj Share News
0.000.00%
Last trade - 00:00TechnologySpeculativeMicro CapNeutral
- €26.86m
- €21.56m
- €9.36m
- 60
- 18
- 50
- 34
BRIEF-Biohit Upgrades 2022 Outlook, Says Prelim H1 EBIT Up At EUR 1.3 Mln
NewsBRIEF-Biohit H2 Operative EBITDA Swings To Profit Of EUR 0.7 Mln
NewsBRIEF-Biohit H1 EBITDA Loss Narrows To EUR 0.2 Mln
NewsBRIEF-Biohit: CE Marked Gastropanel Quick Test On The Market
NewsBRIEF-Päivi Siltala New CEO Of Biohit Oyj
NewsBRIEF-Biohit Oyj Says President And CEO Semi Korpela To Leave The Company
NewsBRIEF-Biohit's CEO Is On Sick Leave
NewsBRIEF-Biohit July-Dec Operative EBITDA Swings To Loss Of EUR 0.2 Million
NewsBRIEF-Biohit H1 Operating EBITDA Swings To Loss Of EUR 1.0 Mln
NewsBRIEF-Biohit 2020 Net Sales Now Seen To Decrease Compared To 2019
NewsBRIEF-Biohit To Convene Annual General Meeting At Later Stage
NewsBRIEF-Biohit H2 Operating EBITDA EUR 0.2 Million
NewsTREATMENT RECOMMENDATION IN RUSSIA: GastroPanel® biomarkers should be used for detection of gastrointestinal diseases
NewsHOITOSUOSITUS VENÄJÄLLÄ: GastroPanel®-biomerkkiaineiden käyttöä edellytetään ruoansulatuskanavan sairauksien toteamisessa
NewsBRIEF-Biohit H1 Operative EBITDA Swings To Profit Of EUR 0.4 Mln
NewsREG-BIOHIT-KONSERNIN PUOLIVUOSIKATSAUS 2019
NewsREG-BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2019
NewsBRIEF-Biohit Concludes Clinical Trials With Acetium
NewsREG-Kahden kliinisen tutkimuksen tulokset Acetium®-kapselin tehosta migreenityyppisten päänsärkykohtausten estäjänä ovat valmistuneet
News